Streetbeat News

INVO

INVO Bioscience, Inc.

https://www.invobio.com

Industry

Medical - Devices

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Open

0.86

Mkt cap

3.3M

Volume

124K

High

0.88

P/E Ratio

1.21

52-wk high

3.50

Low

0.82

Div yield

N/A

52-wk low

0.63

Shares of INVO BioScience have resumed trading.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 1:36 pm

Shares of INVO BioScience have been halted on a circuit breaker to the upside, with the stock now up 209.3%.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 1:33 pm

During Monday's pre-market session, several healthcare stocks experienced significant movements. LumiraDx, INVO Bioscience, Apollomics, TC BioPharm, AcelRx Pharmaceuticals, and SomaLogic saw increases in their share prices, while Revolution Medicines, Mira Pharmaceuticals, Ambrx Biopharma, Catalyst Biosciences, Outlook Therapeutics, and Biocept saw decreases.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 1:06 pm

INVO Bioscience has agreed to acquire NAYA Biosciences in an all-stock transaction. NAYA Biosciences' shareholders will receive 7.3333 shares of INVO for each share of NAYA Biosciences, totaling approximately 18,150,000 shares of INVO. The combined company will operate under the name 'NAYA Biosciences'.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:36 am

During Thursday's intraday session, several healthcare stocks experienced significant movements. Gainers included Ontrak (OTRKP), SeaStar Medical Holding (ICU), Outlook Therapeutics (OTLK), Atreca (BCEL), Biocept (BIOC), and SAB Biotherapeutics (SABS). Losers included RVL Pharmaceuticals (RVLP), Generation Bio (GBIO), INVO Bioscience (INVO), Acurx Pharmaceuticals (ACXP), Assure Hldgs (IONM), and Redhill Biopharma (RDHL).

Portfolio Pulse from Benzinga Insights

October 19, 2023 | 5:31 pm

Healthcare stocks showed significant movement in Wednesday's after-market session. Gritstone Bio, Avinger, BioSig Technologies, Aytu BioPharma, Omeros, and CASI Pharmaceuticals saw increases, with Gritstone Bio leading with a 37% rise. SeaStar Medical Holding, Monogram Orthopaedics, INVO Bioscience, Avalo Therapeutics, Femasys, and Impel Pharmaceuticals experienced decreases, with SeaStar Medical Holding falling by 10%.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 9:31 pm

During Friday's after-market session, several healthcare stocks experienced significant movements. Helius Medical Tech (HSDT), Applied Molecular (AMTI), Cyclacel Pharmaceuticals (CYCC), IGC Pharma (IGC), Yield10 Bioscience (YTEN), and GlucoTrack (GCTK) saw their stocks rise, while Aditxt (ADTX), Axcella Health (AXLA), INVO Bioscience (INVO), Trinity Biotech (TRIB), Celularity (CELU), and SCWorx (WORX) experienced a decrease in their stock prices.

Portfolio Pulse from Benzinga Insights

September 01, 2023 | 9:31 pm

INVO Bioscience reported worse-than-expected Q2 revenue results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 4:53 pm

INVO Bioscience reported Q2 losses of $(3.06) per share, beating the analyst consensus estimate of $(4.20) by 27.14%. However, the company's quarterly sales of $315.90K missed the analyst consensus estimate of $2.96M by 89.33%. This represents a 1230.43% increase in losses and a 116.17% increase in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 14, 2023 | 8:08 pm

During Friday's session, 157 stocks hit new 52-week lows. Among the notable companies were Corteva, American Rebel Holdings, Mullen Automotive, and BNY Mellon Strategic. The stocks that created new 52-week lows on Friday included Avangrid, SolarEdge Technologies, Etsy, UGI, Concentrix, Hawaiian Electric Indus, Equity Commonwealth, Forward Air, Cracker Barrel Old, Petco Health and Wellness, JinkoSolar Holding Co, Olaplex Hldgs, Frontier Group Holdings, Impinj, Safehold, Monro, 3D Sys, TDCX, Everbridge, Silk Road Medical, Cassava Sciences, 23andMe Holding, Wolverine World Wide, Avidity Biosciences, Boston Omaha, John Hancock Premium Div, BioLife Solns, Seres Therapeutics, American Well, Materialise, BNY Mellon Strategic, Southland Holdings, Funko, Fate Therapeutics, Citizens Financial Servs, American Lithium, Emergent BioSolutions, PetMed Express, Sutro Biopharma, Hippo Holdings, Largo, Omega Therapeutics, System1, Benson Hill, Eaton Vance Municipal, Vor Biopharma, Star Hldgs, Origin Mat, Joint, NanoString Technologies, Codexis, ContextLogic, Akoustis Technologies, Cano Health, GeneDx Hldgs, Electrovaya, Kezar Life Sciences, ProPhase Labs, Alaunos Therapeutics, Chimerix, Electriq Power Holdings, DZS, Streamline Health Solns, Eargo, Intercure, Prime Number Acquisition, REE Automotive, TD Hldgs, Carmell Therapeutics, Neuronetics, Kaixin Auto Hldgs, Crown Crafts, Airgain, Ohmyhome, Singular Genomics Sys, First Seacoast Bancorp, Sarcos Technology, Coya Therapeutics, Otonomo Technologies, CareCloud, Aterian, PAVmed, Orgenesis, CalAmp, Imperial Ptrl, Fitell, LQR House, Iridex, OMNIQ, Safeguard Scientifics, Lichen China, Origin Agritech, Atreca, Sunlight Finl Hldgs, Yunji, MediaCo Holding, Trio Petroleum, Cineverse, Lucy Scientific Discovery, Remark Hldgs, Shuttle Pharmaceuticals, Hempacco, Finch Therapeutics Gr, Visionary Education Tech, Marpai, Ontrak, Nogin, Adamis Pharmaceuticals, China Jo-Jo Drugstores, ABVC BioPharma, Fangdd Network Group, SeaStar Medical Holding, Yoshiharu Global, Universe Pharmaceuticals, Redhill Biopharma, Jiuzi Hldgs, Power REIT, Soligenix, Eightco Holdings, JanOne, Avalo Therapeutics, Yield10 Bioscience, Aditxt, Salarius Pharmaceuticals, China Pharma Holding, OpGen, Akanda, Harbor Custom Dev, Biocept, NeuBase Therapeutics, Ucommune International, INVO Bioscience, Esports Entertainment, American Rebel Holdings.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.